Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide continuation with docetaxel plus prednisolone after progression on enzalutamide in chemotherapy-naive mCRPC
NL-OMON47746Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Dec 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Open-label enzalutamide lead-in, Docetaxel + prednisolone + enzalutamide and Docetaxel + prednisolone + placebo (3 arms). Primary endpoint: Progression-free survival. Started Dec 2014; status: completed.
02
Drugs
enzalutamidedocetaxelprednisolone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON47746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47746.